Existing investors WuXi PharmaTech and Mayo Clinic took part in a series B round that will help Unity Biotechnology move preclinical candidates into human trials.

Unity Biotechnology, a US-based developer of treatments for diseases related to aging, closed a $116m series B round backed by medical research companies WuXi PharmaTech and Mayo Clinic yesterday. Financial services group Fidelity Management and Research Company also took part in the round, as did Arch Venture Partners, Baillie Gifford, Partner Fund Management, Venrock and…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.